CompletedNot Applicable

Albumin and Furosemide for Preventing Ovarian Hyperstimulation Syndrome in ICSI Patients

Iraq200 participantsStarted 2019-04-29

Plain-language summary

This study aims to evaluate whether the combination of Albumin and Furosemide can reduce the risk of Ovarian Hyperstimulation Syndrome in women undergoing intracytoplasmic sperm injection (ICSI) who are at high risk of developing this condition. Ovarian hyperstimulation syndrome is a potential complication of ovarian stimulation during assisted reproductive techniques, which can lead to symptoms such as abdominal swelling, fluid accumulation, and, in severe cases, hospitalization. Preventing this condition is important to improve patient safety and treatment outcomes. In this randomized controlled study, eligible women undergoing ICSI were assigned to receive either the combination of albumin and furosemide or standard care. The study compared the occurrence and severity of OHSS between the two groups. The results of this study may help identify an effective strategy to prevent OHSS and improve the safety of assisted reproductive treatments.

Who can participate

Age range

20 Years – 35 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- The inclusion criteria were females aged ≤35 years old, previous history of severe OHSS, AMH\> 3.4, antral follicles count ≥22, presence of \>18 follicles with a diameter \>11 mm at any day of the stimulation cycle, serum estradiol ≥3500 pg/ml at day of hCG trigger, and aspiration of \>15 oocytes at day of oocyte pick up. Exclusion Criteria: * Any female who does not meet those criteria were excluded

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Incidence of Ovarian Hyperstimulation Syndrome

Timeframe: From oocyte retrieval until 14 days after embryo transfer= 14 days

Incidence of Moderate and Severe Ovarian Hyperstimulation Syndrome

Timeframe: Within 14 Days Post Oocyte Retrieval

Trial details

NCT IDNCT07568886

SponsorAl-Nahrain University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-04-27

View on ClinicalTrials.gov More Ovarian Hyper Stimulation Syndrome (OHSS) trials